Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 3/20 | 0.49 |
| ▸ | BRAF | P15056 | 9/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | RAF1 | P04049 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195185 | 0.93 | BRAF (0.51) | SCDBRAFKDRNPC1RAB9A | |
| SCHEMBL2199112 | 0.91 | SCD (0.52) | SCDBRAFKDRNPC1RAB9A | |
| SCHEMBL2854022 | 0.89 | KDR (0.47) | BRAFKDRRAF1YES1 | |
| SCHEMBL2197312 | 0.88 | KDR (0.61) | SCDBRAFKDRLCK | |
| SCHEMBL2192208 | 0.87 | ALDH1A1 (0.54) | BRAFKDRSMN1; SMN2KMT2AKDM4E | |
| SCHEMBL2195711 | 0.86 | SCD (0.47) | SCDBRAFKDRNPC1RAB9A | |
| SCHEMBL2192213 | 0.86 | BRAF (0.47) | SCDBRAFKDRTP53LCK | |
| SCHEMBL2191951 | 0.84 | CASP2 (0.49) | CASP2SCDBRAFKDRNPC1 | |
| SCHEMBL2192266 | 0.82 | BRAF (0.63) | SCDBRAFKDRNPC1RAB9A | |
| SCHEMBL2190423 | 0.82 | BRAF (0.57) | SCDBRAFKDRRAF1YES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181987-B9 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2181987-B1 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8324395-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2181987-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | CASP2 1276/4885SCD 4583/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.